Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: gcrispin who wrote (16919)	5/24/2005 12:54:37 AM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 52153

>>I don't think you can count out PDT especially PDT+triamcinolone. PDT will most likely be used in combination therapy<< I respectfully disagree. I think Visudyne will be gone --or close to gone-- from the market within five years. Triamcinilone is at best a band-aid adjuvant to give Visudyne a little more time. If the Lucentis data turn out to be as good as Monday’s PR hints, I think Lucentis blows Macugen and Visudyne (with or without Triamcinilone) away.